In a nutshell This trial is looking at the effectiveness of 177Lu-PSMA-617 in the treatment of castration-resistant (tumor grows even with hormone therapy) prostate cancer. The main outcome to be measured is overall survival. The details Prostate cancer is an uncontrolled growth of the cells which make up the prostate gland. Prostate...
Read MoreIn a nutshell This study investigated if patients with Hodgkin lymphoma (HL) found in the bones have worse outcomes than patients with HL in the lymph nodes. It was found that having bone HL did not reduce survival of patients. Some background Many patients with HL are cured by treatment. After 5 years, almost 86% of patients survive. When...
Read More
In a nutshell This study compared the effects of stem cell transplant to other newer treatments for recently diagnosed multiple myeloma (MM). The main finding was patients who received stem cell transplant had better outcomes than those who did not. Some background Stem cell transplant involves the transfer of cells to a patient. This is an effective...
Read MoreIn a nutshell This trial aims to test the effectiveness of adding olaparib (Lynparza) to radiotherapy for inflammatory breast cancer. The main outcome measured will be how long the patients survive without the disease coming back in its invasive form. The study is being conducted in the United States. The details Inflammatory breast cancer can be...
Read More
In a nutshell This study evaluated the safety and effectiveness of the BR (bendamustine, rituximab) regimen as a second-line treatment for patients with follicular lymphoma (FL) who had disease progression (tumor growth or spread) after chemoimmunotherapy. The study concluded that this regimen was effective in these patients. Some background...
Read MoreIn a nutshell This study is investigating the effectiveness of brentuximab vedotin (Adcetris) and nivolumab (Opdivo) in early-stage Hodgkin lymphoma (HL). The main outcome that will be measured will be survival without cancer worsening after 18 months. The details There are many different treatments for HL. Each treatment or combination of...
Read More
In a nutshell This study investigated the risk factors of developing lung problems after bleomycin (Blenoxane) treatment for Hodgkin lymphoma (HL). It was found that older age may increase the risk of developing lung problems. Some background Bleomycin is an anti-cancer drug, used to treat many types of cancer. Bleomycin is commonly...
Read More
In a nutshell This study evaluated the value of PET (positron emission tomography) scanning after first-line (primary) chemoimmunotherapy in patients with previously untreated follicular lymphoma (FL). This study concluded that PET scanning is a better imaging technique than CT (computed tomography) for assessing treatment response in these...
Read More
In a nutshell This study investigated the effectiveness of medical cannabis in managing side effects associated with chemotherapy in patients with Hodgkin’s lymphoma (HL). This study concluded that medical cannabis may be effective in relieving therapy-related side effects in these patients. Some background Chemotherapy remains the standard...
Read More
In a nutshell This study investigated the effects of chemotherapy after surgery on cognitive performance (CP; attention, memory and thinking processes) in patients with colorectal cancer. Researchers suggested that patients who received chemotherapy after surgery had a decreased CP. Some background Surgery followed by chemotherapy is the standard...
Read More
In a nutshell This study evaluated the long-term safety and effectiveness of cryoablation (a process that uses extreme cold to destroy tissue) for patients with early prostate cancer. This study found that cryoablation is safe and effective for early-stage prostate cancer. Some background Cryoablation is a treatment option for early-stage prostate...
Read More
In a nutshell This study evaluated the safety and effectiveness of ibritumomab tiuxetan (Zevalin) followed by high-dose chemotherapy and autologous stem cell transplantation (ASCT) in patients with relapsed (cancer recurrence) or refractory (does not respond to treatment) non-Hodgkin’s lymphoma (NHL). This study concluded that ibritumomab tiuxetan...
Read More
